85.04 USD
+1.29 (+1.54%)
85.04 USD
0 (0%)
LMAT gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 185 industry peers in the Health Care Equipment & Supplies industry. LMAT gets an excellent profitability rating and is at the same time showing great financial health properties. LMAT has a correct valuation and a medium growth rate. This makes LMAT very considerable for quality investing!
1. Profitability
1.1 Basic Checks
LMAT had positive earnings in the past year.
LMAT had a positive operating cash flow in the past year.
In the past 5 years LMAT has always been profitable.
Each year in the past 5 years LMAT had a positive operating cash flow.
1.2 Ratios
The Return On Assets of LMAT (8.92%) is better than 91.35% of its industry peers.
The Return On Equity of LMAT (14.08%) is better than 90.27% of its industry peers.
With an excellent Return On Invested Capital value of 8.43%, LMAT belongs to the best of the industry, outperforming 87.03% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for LMAT is in line with the industry average of 8.84%.
The 3 year average ROIC (8.26%) for LMAT is below the current ROIC(8.43%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.92% | ||
| ROE | 14.08% | ||
| ROIC | 8.43% |
ROA(3y)7.77%
ROA(5y)8.17%
ROE(3y)10.28%
ROE(5y)10.74%
ROIC(3y)8.26%
ROIC(5y)8.93%
1.3 Margins
LMAT's Profit Margin of 22.14% is amongst the best of the industry. LMAT outperforms 94.05% of its industry peers.
In the last couple of years the Profit Margin of LMAT has grown nicely.
LMAT's Operating Margin of 25.71% is amongst the best of the industry. LMAT outperforms 95.14% of its industry peers.
LMAT's Operating Margin has improved in the last couple of years.
LMAT has a Gross Margin of 70.97%. This is in the better half of the industry: LMAT outperforms 79.46% of its industry peers.
In the last couple of years the Gross Margin of LMAT has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 25.71% | ||
| PM (TTM) | 22.14% | ||
| GM | 70.97% |
OM growth 3Y0.27%
OM growth 5Y5.61%
PM growth 3Y4.76%
PM growth 5Y5.57%
GM growth 3Y1.48%
GM growth 5Y0.13%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so LMAT is destroying value.
Compared to 1 year ago, LMAT has more shares outstanding
Compared to 5 years ago, LMAT has more shares outstanding
LMAT has a worse debt/assets ratio than last year.
2.2 Solvency
LMAT has an Altman-Z score of 7.19. This indicates that LMAT is financially healthy and has little risk of bankruptcy at the moment.
LMAT has a Altman-Z score of 7.19. This is amongst the best in the industry. LMAT outperforms 84.86% of its industry peers.
The Debt to FCF ratio of LMAT is 2.54, which is a good value as it means it would take LMAT, 2.54 years of fcf income to pay off all of its debts.
LMAT has a better Debt to FCF ratio (2.54) than 84.86% of its industry peers.
LMAT has a Debt/Equity ratio of 0.44. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of LMAT (0.44) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.44 | ||
| Debt/FCF | 2.54 | ||
| Altman-Z | 7.19 |
ROIC/WACC0.87
WACC9.69%
2.3 Liquidity
A Current Ratio of 13.58 indicates that LMAT has no problem at all paying its short term obligations.
LMAT has a better Current ratio (13.58) than 97.84% of its industry peers.
A Quick Ratio of 11.45 indicates that LMAT has no problem at all paying its short term obligations.
LMAT has a better Quick ratio (11.45) than 95.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 13.58 | ||
| Quick Ratio | 11.45 |
3. Growth
3.1 Past
LMAT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 19.67%, which is quite good.
Measured over the past years, LMAT shows a quite strong growth in Earnings Per Share. The EPS has been growing by 17.13% on average per year.
Looking at the last year, LMAT shows a quite strong growth in Revenue. The Revenue has grown by 13.07% in the last year.
The Revenue has been growing by 13.41% on average over the past years. This is quite good.
EPS 1Y (TTM)19.67%
EPS 3Y15.47%
EPS 5Y17.13%
EPS Q2Q%26.53%
Revenue 1Y (TTM)13.07%
Revenue growth 3Y12.5%
Revenue growth 5Y13.41%
Sales Q2Q%11.36%
3.2 Future
Based on estimates for the next years, LMAT will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.10% on average per year.
LMAT is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.65% yearly.
EPS Next Y27.49%
EPS Next 2Y16.63%
EPS Next 3Y14.06%
EPS Next 5Y11.1%
Revenue Next Year12.78%
Revenue Next 2Y10.91%
Revenue Next 3Y10.19%
Revenue Next 5Y9.65%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
LMAT is valuated quite expensively with a Price/Earnings ratio of 38.83.
Compared to the rest of the industry, the Price/Earnings ratio of LMAT indicates a somewhat cheap valuation: LMAT is cheaper than 71.35% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.00, LMAT is valued a bit more expensive.
The Price/Forward Earnings ratio is 32.23, which means the current valuation is very expensive for LMAT.
LMAT's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. LMAT is cheaper than 72.43% of the companies in the same industry.
LMAT is valuated rather expensively when we compare the Price/Forward Earnings ratio to 23.70, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 38.83 | ||
| Fwd PE | 32.23 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, LMAT is valued a bit cheaper than the industry average as 78.38% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of LMAT indicates a rather cheap valuation: LMAT is cheaper than 81.08% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 29.14 | ||
| EV/EBITDA | 19.5 |
4.3 Compensation for Growth
LMAT's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
LMAT has an outstanding profitability rating, which may justify a higher PE ratio.
LMAT's earnings are expected to grow with 14.06% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.41
PEG (5Y)2.27
EPS Next 2Y16.63%
EPS Next 3Y14.06%
5. Dividend
5.1 Amount
LMAT has a yearly dividend return of 0.99%, which is pretty low.
Compared to an average industry Dividend Yield of 0.20, LMAT pays a better dividend. On top of this LMAT pays more dividend than 91.89% of the companies listed in the same industry.
With a Dividend Yield of 0.99, LMAT pays less dividend than the S&P500 average, which is at 1.94.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.99% |
5.2 History
On average, the dividend of LMAT grows each year by 13.60%, which is quite nice.
LMAT has been paying a dividend for at least 10 years, so it has a reliable track record.
LMAT has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)13.6%
Div Incr Years13
Div Non Decr Years13
5.3 Sustainability
LMAT pays out 32.20% of its income as dividend. This is a sustainable payout ratio.
LMAT's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP32.2%
EPS Next 2Y16.63%
EPS Next 3Y14.06%
85.04
+1.29 (+1.54%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners95.2%
Inst Owner Change0%
Ins Owners7.98%
Ins Owner Change-4.67%
Market Cap1.93B
Revenue(TTM)240.87M
Net Income(TTM)53.34M
Analysts78.82
Price Target105.74 (24.34%)
Short Float %5.41%
Short Ratio6.52
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.99% |
Yearly Dividend0.64
Dividend Growth(5Y)13.6%
DP32.2%
Div Incr Years13
Div Non Decr Years13
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.59%
Min EPS beat(2)3.81%
Max EPS beat(2)7.38%
EPS beat(4)2
Avg EPS beat(4)0.79%
Min EPS beat(4)-5.52%
Max EPS beat(4)7.38%
EPS beat(8)6
Avg EPS beat(8)4.68%
EPS beat(12)9
Avg EPS beat(12)4.66%
EPS beat(16)9
Avg EPS beat(16)-0.71%
Revenue beat(2)1
Avg Revenue beat(2)-1.47%
Min Revenue beat(2)-3.74%
Max Revenue beat(2)0.79%
Revenue beat(4)2
Avg Revenue beat(4)-0.88%
Min Revenue beat(4)-3.74%
Max Revenue beat(4)1.83%
Revenue beat(8)4
Avg Revenue beat(8)-0.49%
Revenue beat(12)6
Avg Revenue beat(12)-0.01%
Revenue beat(16)7
Avg Revenue beat(16)-0.44%
PT rev (1m)-0.64%
PT rev (3m)-1.06%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.07%
EPS NY rev (1m)-0.19%
EPS NY rev (3m)6.22%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.16%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.94%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 38.83 | ||
| Fwd PE | 32.23 | ||
| P/S | 8.01 | ||
| P/FCF | 29.14 | ||
| P/OCF | 26.33 | ||
| P/B | 5.09 | ||
| P/tB | 6.86 | ||
| EV/EBITDA | 19.5 |
EPS(TTM)2.19
EY2.58%
EPS(NY)2.64
Fwd EY3.1%
FCF(TTM)2.92
FCFY3.43%
OCF(TTM)3.23
OCFY3.8%
SpS10.62
BVpS16.7
TBVpS12.4
PEG (NY)1.41
PEG (5Y)2.27
Graham Number28.69
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.92% | ||
| ROE | 14.08% | ||
| ROCE | 10.97% | ||
| ROIC | 8.43% | ||
| ROICexc | 21.47% | ||
| ROICexgc | 38.36% | ||
| OM | 25.71% | ||
| PM (TTM) | 22.14% | ||
| GM | 70.97% | ||
| FCFM | 27.5% |
ROA(3y)7.77%
ROA(5y)8.17%
ROE(3y)10.28%
ROE(5y)10.74%
ROIC(3y)8.26%
ROIC(5y)8.93%
ROICexc(3y)14.32%
ROICexc(5y)13.54%
ROICexgc(3y)28.83%
ROICexgc(5y)29.82%
ROCE(3y)10.75%
ROCE(5y)11.62%
ROICexgc growth 3Y-0.4%
ROICexgc growth 5Y7.52%
ROICexc growth 3Y9.22%
ROICexc growth 5Y8.43%
OM growth 3Y0.27%
OM growth 5Y5.61%
PM growth 3Y4.76%
PM growth 5Y5.57%
GM growth 3Y1.48%
GM growth 5Y0.13%
F-Score5
Asset Turnover0.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.44 | ||
| Debt/FCF | 2.54 | ||
| Debt/EBITDA | 2.33 | ||
| Cap/Depr | 68.51% | ||
| Cap/Sales | 2.93% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 101.46% | ||
| Profit Quality | 124.17% | ||
| Current Ratio | 13.58 | ||
| Quick Ratio | 11.45 | ||
| Altman-Z | 7.19 |
F-Score5
WACC9.69%
ROIC/WACC0.87
Cap/Depr(3y)60.87%
Cap/Depr(5y)52.43%
Cap/Sales(3y)2.97%
Cap/Sales(5y)2.88%
Profit Quality(3y)96.62%
Profit Quality(5y)110.46%
High Growth Momentum
Growth
EPS 1Y (TTM)19.67%
EPS 3Y15.47%
EPS 5Y17.13%
EPS Q2Q%26.53%
EPS Next Y27.49%
EPS Next 2Y16.63%
EPS Next 3Y14.06%
EPS Next 5Y11.1%
Revenue 1Y (TTM)13.07%
Revenue growth 3Y12.5%
Revenue growth 5Y13.41%
Sales Q2Q%11.36%
Revenue Next Year12.78%
Revenue Next 2Y10.91%
Revenue Next 3Y10.19%
Revenue Next 5Y9.65%
EBIT growth 1Y24.85%
EBIT growth 3Y12.81%
EBIT growth 5Y19.77%
EBIT Next Year45.26%
EBIT Next 3Y22.27%
EBIT Next 5YN/A
FCF growth 1Y189.96%
FCF growth 3Y7.14%
FCF growth 5Y28.96%
OCF growth 1Y143.52%
OCF growth 3Y7.93%
OCF growth 5Y25.49%
LEMAITRE VASCULAR INC / LMAT FAQ
What is the ChartMill fundamental rating of LEMAITRE VASCULAR INC (LMAT) stock?
ChartMill assigns a fundamental rating of 7 / 10 to LMAT.
What is the valuation status of LEMAITRE VASCULAR INC (LMAT) stock?
ChartMill assigns a valuation rating of 5 / 10 to LEMAITRE VASCULAR INC (LMAT). This can be considered as Fairly Valued.
How profitable is LEMAITRE VASCULAR INC (LMAT) stock?
LEMAITRE VASCULAR INC (LMAT) has a profitability rating of 9 / 10.
What is the valuation of LEMAITRE VASCULAR INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for LEMAITRE VASCULAR INC (LMAT) is 38.83 and the Price/Book (PB) ratio is 5.09.
How financially healthy is LEMAITRE VASCULAR INC?
The financial health rating of LEMAITRE VASCULAR INC (LMAT) is 7 / 10.